KR101823451B1 - 퀴논계 화합물, 이의 광학 이성질체 및 이의 제조 방법과 의약 용도 - Google Patents

퀴논계 화합물, 이의 광학 이성질체 및 이의 제조 방법과 의약 용도 Download PDF

Info

Publication number
KR101823451B1
KR101823451B1 KR1020167003638A KR20167003638A KR101823451B1 KR 101823451 B1 KR101823451 B1 KR 101823451B1 KR 1020167003638 A KR1020167003638 A KR 1020167003638A KR 20167003638 A KR20167003638 A KR 20167003638A KR 101823451 B1 KR101823451 B1 KR 101823451B1
Authority
KR
South Korea
Prior art keywords
hydroxy
group
acid
octane
ethoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020167003638A
Other languages
English (en)
Korean (ko)
Other versions
KR20160033146A (ko
Inventor
춘징 왕
준이 왕
쩌준 가오
Original Assignee
베이징 에프에스웰컴 테크놀로지 디벨롭먼트 컴퍼니 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 베이징 에프에스웰컴 테크놀로지 디벨롭먼트 컴퍼니 리미티드 filed Critical 베이징 에프에스웰컴 테크놀로지 디벨롭먼트 컴퍼니 리미티드
Publication of KR20160033146A publication Critical patent/KR20160033146A/ko
Application granted granted Critical
Publication of KR101823451B1 publication Critical patent/KR101823451B1/ko
Assigned to 베이징 서우바이 파마슈티컬 컴퍼니 리미티드 reassignment 베이징 서우바이 파마슈티컬 컴퍼니 리미티드 권리의 전부이전등록 Assignors: 베이징 에프에스웰컴 테크놀로지 디벨롭먼트 컴퍼니 리미티드
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/49—Cinchonan derivatives, e.g. quinine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
KR1020167003638A 2013-07-13 2014-07-11 퀴논계 화합물, 이의 광학 이성질체 및 이의 제조 방법과 의약 용도 Active KR101823451B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201310297901 2013-07-13
CN201310297901.7 2013-07-13
PCT/CN2014/000669 WO2015007073A1 (zh) 2013-07-13 2014-07-11 奎宁类化合物、其光学异构体及其制备方法和医药用途

Publications (2)

Publication Number Publication Date
KR20160033146A KR20160033146A (ko) 2016-03-25
KR101823451B1 true KR101823451B1 (ko) 2018-01-30

Family

ID=52345746

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020167003638A Active KR101823451B1 (ko) 2013-07-13 2014-07-11 퀴논계 화합물, 이의 광학 이성질체 및 이의 제조 방법과 의약 용도

Country Status (13)

Country Link
US (1) US9751875B2 (https=)
EP (1) EP3023424B1 (https=)
JP (1) JP6218940B2 (https=)
KR (1) KR101823451B1 (https=)
CN (1) CN105431432B (https=)
AU (1) AU2014292722B2 (https=)
BR (1) BR112016000629B1 (https=)
CA (1) CA2921621C (https=)
ES (1) ES2726664T3 (https=)
RU (1) RU2641285C2 (https=)
TR (1) TR201906532T4 (https=)
WO (1) WO2015007073A1 (https=)
ZA (1) ZA201600997B (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6693943B2 (ja) * 2015-03-02 2020-05-13 株式会社Ｌｔｔバイオファーマ キヌクリジン誘導体
CA3047023C (en) 2016-12-14 2022-05-31 Beijing Showby Pharmaceutical Co., Ltd. Class of bifunctional compounds with quaternary ammonium salt structure
CN109824661B (zh) * 2019-03-30 2020-06-05 山东博洛德生物科技有限公司 一种盐酸戊乙奎醚中杂质的制备方法
CN109824662A (zh) * 2019-03-30 2019-05-31 山东博洛德生物科技有限公司 一种奎宁类化合物及其制备方法
CN109776521A (zh) * 2019-03-30 2019-05-21 山东博洛德生物科技有限公司 一种含有季铵基团的奎宁类化合物及其制备方法
CA3181333A1 (en) * 2020-04-26 2021-11-04 Beijing Showby Pharmaceutical Co., Ltd. Crystals, preparation method and application of a muscarinic receptor antagonist
CN114306331B (zh) * 2020-10-10 2023-07-18 远大生命科学(武汉)有限公司 戊乙奎醚在治疗或预防视力损伤性眼部疾病中的用途
CN118555954B (zh) * 2022-01-19 2025-11-04 北京硕佰医药科技有限责任公司 一种治疗鼻炎的溶液型鼻喷雾剂及制备方法
CN116514800A (zh) * 2023-05-06 2023-08-01 湖南一格制药有限公司 盐酸戊乙奎醚的制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102070631A (zh) * 2009-11-20 2011-05-25 中国人民解放军军事医学科学院毒物药物研究所 戊乙奎醚光学异构体的季铵盐、药物组合物及其医药用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1219606A (en) 1968-07-15 1971-01-20 Rech S Et D Applic Scient Soge Quinuclidinol derivatives and preparation thereof
DE4108393A1 (de) 1991-03-15 1992-09-17 Boehringer Ingelheim Kg Neue ester bi- und tricyclischer aminoalkohole, ihre herstellung und ihre verwendung in arzneimitteln
NO2005012I1 (no) * 1994-12-28 2005-06-06 Debio Rech Pharma Sa Triptorelin og farmasoytisk akseptable salter derav
ES2165768B1 (es) * 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
CZ294251B6 (cs) * 2000-06-27 2004-11-10 Laboratorios S. A. L. V. A. T., S. A. Karbamáty a jejich použití pro výrobu farmaceutického prostředku
IL156558A0 (en) * 2000-12-28 2004-01-04 Almirall Prodesfarma Ag Novel quinuclidine derivatives and medicinal compositions containing the same
ES2203327B1 (es) * 2002-06-21 2005-06-16 Almirall Prodesfarma, S.A. Nuevos carbamatos de quinuclidina y composiciones farmaceuticas que los contienen.
ES2204295B1 (es) * 2002-07-02 2005-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de quinuclidina-amida.
PE20060259A1 (es) 2004-04-27 2006-03-25 Glaxo Group Ltd Compuestos de quinuclidina como antagonistas del receptor de acetilcolina muscarinico
JP4637715B2 (ja) * 2005-10-17 2011-02-23 日信工業株式会社 車両用支持構造体の製造方法
CN1951938A (zh) * 2005-10-21 2007-04-25 刘丽娅 戊乙奎醚季铵盐及其衍生物
AU2007336054A1 (en) * 2006-12-19 2008-06-26 Astrazeneca Ab Quinuclidinol derivatives as muscarinic receptor antagonists
KR20090107567A (ko) * 2007-02-09 2009-10-13 아스텔라스세이야쿠 가부시키가이샤 아자 가교환 화합물
CN102850344A (zh) * 2011-06-28 2013-01-02 中国人民解放军军事医学科学院毒物药物研究所 戊乙奎醚光学异构体衍生物用于抗肿瘤的医药用途

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102070631A (zh) * 2009-11-20 2011-05-25 中国人民解放军军事医学科学院毒物药物研究所 戊乙奎醚光学异构体的季铵盐、药物组合物及其医药用途

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
J. Med. Chem., 2009, 52, 2493-2505.

Also Published As

Publication number Publication date
BR112016000629B1 (pt) 2023-10-31
CA2921621A1 (en) 2015-01-22
CA2921621C (en) 2018-08-28
EP3023424A4 (en) 2017-01-18
CN105431432B (zh) 2018-01-09
EP3023424A1 (en) 2016-05-25
ES2726664T3 (es) 2019-10-08
US9751875B2 (en) 2017-09-05
KR20160033146A (ko) 2016-03-25
CN105431432A (zh) 2016-03-23
WO2015007073A1 (zh) 2015-01-22
EP3023424B1 (en) 2019-02-27
BR112016000629A2 (https=) 2017-07-25
RU2641285C2 (ru) 2018-01-17
TR201906532T4 (tr) 2019-05-21
ZA201600997B (en) 2018-05-30
RU2016104437A (ru) 2017-08-16
JP6218940B2 (ja) 2017-10-25
US20160244439A1 (en) 2016-08-25
AU2014292722A1 (en) 2016-03-03
AU2014292722B2 (en) 2017-03-09
JP2016528199A (ja) 2016-09-15

Similar Documents

Publication Publication Date Title
KR101823451B1 (ko) 퀴논계 화합물, 이의 광학 이성질체 및 이의 제조 방법과 의약 용도
JP3981357B2 (ja) 第４級アンモニウム化合物および抗ムスカリン剤としてのそれらの使用
KR101996245B1 (ko) 선택적 s1p1 수용체 아고니스트를 포함하는 약학 조합물
TW201011022A (en) Quinuclidine carbonate derivatives and medicinal composition thereof
CN113272298B (zh) 用于治疗呼吸系统疾病的化合物和组合物
JPH03504010A (ja) ジベンゾフランカルボキサミド
CN102070631B (zh) 戊乙奎醚光学异构体的季铵盐、药物组合物及其医药用途
JP6030120B2 (ja) Ｃｎｓ障害の治療におけるジベンゾチアゼピン誘導体およびその使用
US8394824B2 (en) Quinuclidine compounds having quaternary ammonium group, its preparation method and use as blocking agents of acetylcholine
CN110372557A (zh) 环己烷胺类d3/d2受体部分激动剂
JP7498504B2 (ja) 脳神経または心臓保護剤としてのアミノチオール系化合物の使用
WO2020183227A1 (en) Treating influenza using substituted polycyclic pyridone derivatives and prodrugs thereof in a subject having influenza and a complication risk factor
CN118613258A (zh) 8-甲基-8-氮杂双环[3.2.1]辛-3-基3-羟基-2-苯基丙酸酯的酯
JP2013503908A (ja) ニューロキニン２受容体活性に関連する障害または疾患を治療するための化合物
CN116554144B (zh) 一种sj系列芳基苯胺类化合物及其制备方法与医药用途
WO2020094634A1 (en) Thiophene prodrugs of naltroxene for long-acting injectable compositions and related methods

Legal Events

Date Code Title Description
A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R17-X000 Change to representative recorded

St.27 status event code: A-5-5-R10-R17-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R14-asn-PN2301

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 8